L D Kaufman1. 1. Division of Allergy, Rheumatology, and Clinical Immunology, State University of New York at Stony Brook 11794-8161.
Abstract
OBJECTIVE: To define the natural history and outcome of eosinophilia-myalgia syndrome (EMS) among a cohort of patients followed up at one center since the onset of their disease. METHODS: Fifty-seven patients with well-characterized EMS were evaluated prospectively at a university hospital for 21-64 months (mean 36 months). RESULTS: Eighty-eight percent of the patients continue to have symptomatic disease with > 3 clinical manifestations. Fatigue (91%), muscle cramping (75%), myalgia (70%), paresthesias with objectively demonstrated hypesthesias (62%), articular symptoms (54%), scleroderma-like skin changes (44%), and proximal muscle weakness (40%) are the most common features of chronic EMS. New findings identified among this cohort include cognitive symptoms in 86% of the study group, tremor, and myoclonus. CONCLUSION: The recognition of new manifestations in EMS and ongoing clinical disease in 88% of patients highlights the chronic nature of this disorder. Continued prospective followup of a large patient base is warranted to further define the natural history of this newly recognized illness.
OBJECTIVE: To define the natural history and outcome of eosinophilia-myalgia syndrome (EMS) among a cohort of patients followed up at one center since the onset of their disease. METHODS: Fifty-seven patients with well-characterized EMS were evaluated prospectively at a university hospital for 21-64 months (mean 36 months). RESULTS: Eighty-eight percent of the patients continue to have symptomatic disease with > 3 clinical manifestations. Fatigue (91%), muscle cramping (75%), myalgia (70%), paresthesias with objectively demonstrated hypesthesias (62%), articular symptoms (54%), scleroderma-like skin changes (44%), and proximal muscle weakness (40%) are the most common features of chronic EMS. New findings identified among this cohort include cognitive symptoms in 86% of the study group, tremor, and myoclonus. CONCLUSION: The recognition of new manifestations in EMS and ongoing clinical disease in 88% of patients highlights the chronic nature of this disorder. Continued prospective followup of a large patient base is warranted to further define the natural history of this newly recognized illness.